メタボリックシンドローム患者における高濃度水素水24週間摂取が体組成・血中脂質・炎症バイオマーカーに及ぼす影響：無作為化対照試験
A 24-week, double-blind, placebo-controlled randomized trial enrolled 60 adults (30 men and 30 women) diagnosed with metabolic syndrome. Participants received either high-concentration hydrogen-rich water (exceeding 5.5 mmol H2 per day) or placebo following a one-week baseline observation period. Compared with placebo, hydrogen-rich water supplementation produced statistically significant reductions in blood cholesterol and fasting glucose concentrations, along with decreased hemoglobin A1c levels (p < 0.05). Markers associated with systemic inflammation and redox homeostasis also improved in the hydrogen group. Additionally, modest decreases in body mass index and waist-to-hip ratio were observed, though these trends did not reach the primary significance threshold. These findings suggest that prolonged intake of high-concentration hydrogen-rich water may favorably influence multiple cardiometabolic risk factors in individuals with metabolic syndrome.
Molecular hydrogen is proposed to selectively scavenge reactive oxygen species, thereby reducing oxidative stress. This antioxidant action is thought to suppress chronic inflammation and restore cellular redox homeostasis, contributing to improvements in lipid metabolism and glycemic regulation.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/32273740